DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated July 19, 2006, and published in the **Federal Register** on July 26, 2006, (71 FR 42417), Lin Zhi International, Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Tetrahydrocannabinols (7370) 3,4–Methylenedioxy-methamphetamine (7405). Cocaine (9041) Oxycodone (9143) Hydrocodone (9193) Methadone (9250) Dextropropoxyphene, bulk (9273) Morphine (9300)	

The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Lin Zhi International, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Lin Zhi International, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: November 28, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20693 Filed 12–6–06; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated July 10, 2006 and published in the **Federal Register** on July 24, 2006, (71 FR 41837–41838), Lipomed Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Cathinone (1235)	1
Methcathinone (1237)	li
N-Ethylamphetamine (1475)	li
Methaqualone (2565)	1
Gamma hydroxybutyric acid	1
(2010).	
Lysergic acid diethylamide (7315),	1
2,5-Dimethoxy-4-(n)-	
propylthiophenethylamine	
(7438).	
Marihuana (7360)	1
Tetrahydrocannabinols (7370)	ļ ļ
Mescaline (7381)	ļ ļ
3,4,5-Trimethoxyamphetamine	
(7390).	
4-Bromo-2,5-	1
dimethoxyamphetamine (7391).	
4-Bromo-2,5-	I
dimethoxyphenethylamine	
(7392).	
4-Methyl-2,5-	I
dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine	1
(7396).	ļ !
2,5-Dimethoxy-4-	l i
ethylamphetamine (7399).	'
3,4-Methylenedioxyamphetamine	l i
(7400).	
3,4-Methylenedioxy-N-	l i
ethylamphetamine (7404).	
3,4-	1
Methylenedioxymethamphetam-	
ine (7405).	
4-Methoxyamphetamine (7411)	1
Dimethyltryptamine (7435)	1
Psilocybin (7437)	ļ ļ
Psilocyn (7438)	!
Acetyldihydrocodeine (9051)	
Dihydromorphine (9145)	
Heroin (9200)	1
Normorphine (9313)	
Pholcodine (9314)	i i
Tilidine (9750) Amphetamine (1100)	i
Methamphetamine (1105)	l'ii
Amobarbital (2125)	l ii
Pentobarbital (2270)	l ii
Secobarbital (2315)	Lii
Phencyclidine (7471)	lii
Cocaine (9041)	ii
Codeine (9050)	ii
Codeine (9050) Dihydrocodeine (9120)	II
Oxycodone (9143)	Ш
Hydromorphone (9150)	II
Bonzovloggonino (0190)	11

Benzoylecgonine (9180) II

Drug	Schedule
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Lévorphanol (9220)	II
Meperidine (9230)	П
Methadone (9250)	П
Dextropropoxyphene, bulk (non-	II
dosage forms) (9273).	
Morphine (9300)	II
Thebaine (9333)	П
Oxymorphone (9652)	П
Alfentanil (9737)	П
Fentanyl (9801)	lii
Sufentanil (9740)	II

The company plans to import analytical reference standards for distribution to its customers for research and analytical purposes.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Lipomed Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Lipomed Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with State and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: November 28, 2006.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E6–20745 Filed 12–6–06; 8:45 am] **BILLING CODE 4410–09–P**

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated July 25, 2006, and published in the **Federal Register** on July 31, 2006, (71 FR 43211), MGI Pharma, 6611 Tributary Street, Baltimore, Maryland 21224, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041),